Summary
Background: Recombinant platelet factor 4 (rPF4) is a naturally occurring protein found in platelet alpha granules that can inhibit angiogenesis.
Methods: In this Phase I trial, 9 patients with metastatic colorectal cancer who had failed 5-FU treatment received rPF4 at doses ranging from 0.3 to 3.0 mg/kg via 30-minute infusion. Three additional patients were treated with the 3 mg/kg dose over a 6-hour period of infusion.
Results: The only toxicity encountered was mild leg twitching in 2/3 patients treated with the 6-hour infusion. One patient with a history of phlebitis developed a lower extremity deep venous thrombosis after the first dose of rPF4. A mild rise in fibrinogen level was noted in several patients. Of the 11 evaluable patients, there were no clinical responses to treatment.
Conclusions: rPF4 is well tolerated at the doses and schedules tested. No clinical responses were observed. Prolonged infusion schedules should be investigated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Willett CG, Tepper JE, Cohen AM et al.: Failure patterns following curative resection of colon carcinoma. Ann Surg 200:685–690, 1984
Willett CG, Tepper JE, Cohen AM et al.: Local failure following curative resection of colonic adenocarcinoma. Int J Radiat Oncol Biol Phy 10:645–651, 1984
Eisenberg B, DeCrosse JJ, Harford F et al.: Carcinoma of the colon and rectum: natural history. N Engl J Med 266:211–219, 1962
Panettiere FJ, Chen TT: The SWOG large bowel study. Proc Am Soc Clin Onc 4:76, 1985
Grage TB, Moss SE: Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5FU chemotherapy. Surg Clin N America 61:1321–1329, 1981
Laurie J, Moertel C, Flemming T et al.: Surgical adjuvant therapy of poor prognosis colorectal cancer with levamisole alone or in combination with 5FU: a North Central Oncology Group study. Proc Am Soc Clin Onc 5:81, 1986
Data on file: Repligen Corporation
Maione TE, Gray GS, Petro J et al.: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 237:77–79, 1990
Sharpe RJ, Randolph HR, Scott CF et al.: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82:848–853, 1990
Broxmeyer HE, Sherry B, Cooper S et al.: Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol 150:3348–3458, 1993
Kuna P, Reddigari SR, Rucinski D et al.: Inhibition of MCAF/MCP-1-induced histamine release from human basophils by RANTES. MIP-1a, MIP-1b, PF4, CTAP-III, IL-8 & IP-10 (abstr). J Allergy Clin Immunol 91:314, 1993
Zucker MB, Katz IR: Platelet factor 4: production, structure and physiologic and immunologic action. Proc Soc Exp Biol Med 198:693–702, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Belman, N., Bonnem, E.M., Harvey, H.A. et al. Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs 14, 387–389 (1996). https://doi.org/10.1007/BF00180815
Issue Date:
DOI: https://doi.org/10.1007/BF00180815